These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34464521)

  • 1. Measurement-based Diagnosis and Treatment for Tardive Dyskinesia.
    Correll CU; Citrome L
    J Clin Psychiatry; 2021 Aug; 82(5):. PubMed ID: 34464521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Treatment Fundamentals for Tardive Dyskinesia.
    Correll CU; Citrome L
    J Clin Psychiatry; 2021 Oct; 82(6):. PubMed ID: 34644461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management.
    Sreeram V; Shagufta S; Kagadkar F
    Cureus; 2019 Aug; 11(8):e5471. PubMed ID: 31641566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprint of: Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2018 Jun; 389():61-66. PubMed ID: 29519687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.
    Ward KM; Citrome L
    Neurol Ther; 2018 Dec; 7(2):233-248. PubMed ID: 30027457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review.
    Meyer JM; Chepke C; Bera RB; Pérez-Rodríguez MM; Lundt L; Franey EG; Dhanda R; Benning B; Bron M; Yonan C
    Ment Health Clin; 2023 Oct; 13(5):225-232. PubMed ID: 38131059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
    Correll CU; Kane JM; Citrome LL
    J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective.
    Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA
    Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
    Touma KTB; Scarff JR
    Innov Clin Neurosci; 2018 Jun; 15(5-6):13-16. PubMed ID: 30013814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.